Literature DB >> 27314914

AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.

Roberto Calcedo1, James M Wilson1.   

Abstract

Cross-sectional studies of primates have revealed that natural neutralizing antibody (NAb) responses to adeno-associated viruses (AAV) span multiple serotypes. This differs from the phenotype of the NAb response to an AAV vector delivered to seronegative nonhuman primates that is typically restricted to the administered AAV serotype. To better understand the mechanism by which natural AAV infections result in broad NAb responses, we conducted a longitudinal study spanning 10 years in which we evaluated serum-circulating AAV NAb levels in captive-housed chimpanzees. In a cohort of 25 chimpanzees we identified 3 distinct groups of animals: those that never seroconverted to AAV (naïve), those that were persistently seropositive (chronic), and those that seroconverted during the 10-year period (acute). For the chronic group we found a broad seroresponse characterized by NAbs reacting to multiple AAV serotypes. A similar cross-neutralization pattern of NAbs was observed in the acute group. These data support our hypothesis that a single natural infection with AAV induces a broadly cross-reactive NAb response to multiple AAV serotypes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27314914      PMCID: PMC4932656          DOI: 10.1089/humc.2016.048

Source DB:  PubMed          Journal:  Hum Gene Ther Clin Dev        ISSN: 2324-8637            Impact factor:   5.032


  26 in total

1.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

2.  Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.

Authors:  B Greenberg; J Butler; G M Felker; P Ponikowski; A A Voors; J M Pogoda; R Provost; J Guerrero; R J Hajjar; K M Zsebo
Journal:  Gene Ther       Date:  2015-12-24       Impact factor: 5.250

3.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

4.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.

Authors:  Lili Wang; Roberto Calcedo; Peter Bell; Jianping Lin; Rebecca L Grant; Don L Siegel; James M Wilson
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

5.  Detection of adeno-associated virus type 2 sequences in the human genital tract.

Authors:  M Friedman-Einat; Z Grossman; F Mileguir; Z Smetana; M Ashkenazi; G Barkai; N Varsano; E Glick; E Mendelson
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

6.  Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.

Authors:  Kleopatra Rapti; Vedell Louis-Jeune; Erik Kohlbrenner; Kiyotake Ishikawa; Dennis Ladage; Sergei Zolotukhin; Roger J Hajjar; Thomas Weber
Journal:  Mol Ther       Date:  2011-09-13       Impact factor: 11.454

7.  Adeno-associated virus antibody profiles in newborns, children, and adolescents.

Authors:  Roberto Calcedo; Hiroki Morizono; Lili Wang; Robert McCarter; Jianping He; David Jones; Mark L Batshaw; James M Wilson
Journal:  Clin Vaccine Immunol       Date:  2011-07-20

8.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

9.  Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.

Authors:  Chen Ling; Yuan Wang; Ying-lu Feng; Ya-ni Zhang; Jun Li; Xin-rui Hu; Li-na Wang; Mao-feng Zhong; Xiao-feng Zhai; Irene Zolotukhin; Arun Srivastava; Chang-quan Ling
Journal:  J Integr Med       Date:  2015-09

10.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079

View more
  25 in total

1.  Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.

Authors:  Deborah A Zygmunt; Kelly E Crowe; Kevin M Flanigan; Paul T Martin
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

2.  Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases.

Authors:  Alessia De Caneva; Fabiola Porro; Giulia Bortolussi; Riccardo Sola; Michela Lisjak; Adi Barzel; Mauro Giacca; Mark A Kay; Kristian Vlahoviček; Lorena Zentilin; Andrés F Muro
Journal:  JCI Insight       Date:  2019-06-18

3.  Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.

Authors:  April R Giles; Lakshmanan Govindasamy; Suryanarayan Somanathan; James M Wilson
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 4.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 5.  Delivering AAV to the Central Nervous and Sensory Systems.

Authors:  Cole W Peters; Casey A Maguire; Killian S Hanlon
Journal:  Trends Pharmacol Sci       Date:  2021-04-13       Impact factor: 17.638

Review 6.  Adeno-Associated Virus Gene Therapy for Liver Disease.

Authors:  Lisa M Kattenhorn; Christopher H Tipper; Lorelei Stoica; Deborah S Geraghty; Teresa L Wright; K Reed Clark; Samuel C Wadsworth
Journal:  Hum Gene Ther       Date:  2016-12       Impact factor: 5.695

Review 7.  Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.

Authors:  Sebastian P Fuchs; Ronald C Desrosiers
Journal:  Mol Ther Methods Clin Dev       Date:  2016-11-16       Impact factor: 6.698

Review 8.  A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.

Authors:  Ebony N Gary; Michele A Kutzler
Journal:  Clin Med Insights Pathol       Date:  2017-03-30

9.  Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors.

Authors:  Daniel Stone; Elizabeth J Kenkel; Michelle A Loprieno; Motoko Tanaka; Harshana S De Silva Feelixge; Arjun J Kumar; Laurence Stensland; Willimark M Obenza; Solomon Wangari; Chul Y Ahrens; Robert D Murnane; Christopher W Peterson; Hans-Peter Kiem; Meei-Li Huang; Martine Aubert; Shiu-Lok Hu; Keith R Jerome
Journal:  Hum Gene Ther       Date:  2020-11-02       Impact factor: 5.695

10.  Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.

Authors:  Klaudia Kuranda; Priscilla Jean-Alphonse; Christian Leborgne; Romain Hardet; Fanny Collaud; Solenne Marmier; Helena Costa Verdera; Giuseppe Ronzitti; Philippe Veron; Federico Mingozzi
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.